Novel pathways and therapies in experimental diabetic atherosclerosis

References

• Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care16(2), 434–444 (1993).
   PubMed Web of Science ®Google Scholar
• Candido R, Allen TJ, Lassila M et al. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation109(12), 1536–1542 (2004).
   PubMed Web of Science ®Google Scholar
• Candido R, Jandeleit-Dahm KA, Cao Z et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation106(2), 246–253 (2002).
   PubMed Web of Science ®Google Scholar
• El-Osta A, Brasacchio D, Yao D et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J. Exp. Med.205(10), 2409–2417 (2008).
   PubMed Web of Science ®Google Scholar
• Hsueh W, Abel ED, Breslow JL et al. Recipes for creating animal models of diabetic cardiovascular disease. Circ. Res.100(10), 1415–1427 (2007).
   PubMed Web of Science ®Google Scholar
• Cao Z, Cooper ME, Wu LL et al. Blockade of the renin–angiotensin and endothelin systems on progressive renal injury. Hypertension36(4), 561–568 (2000).
   PubMed Web of Science ®Google Scholar
• No authors listed. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet355(9200), 253–259 (2000).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet359(9311), 1004–1010 (2002).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med.358(15), 1547–1559 (2008).
   PubMed Web of Science ®Google Scholar
• Parving HH, Brenner BM, McMurray JJ et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association – European Renal Association. Nephrol. Dial. Transplant.24(5), 1663–1671 (2009).
   PubMed Web of Science ®Google Scholar
• Cao Z, Bonnet F, Candido R et al. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J. Am. Soc. Nephrol.13(7), 1773–1787 (2002).
   PubMed Web of Science ®Google Scholar
• Cao Z, Kelly DJ, Cox A et al. Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int.58(6), 2437–2451 (2000).
   PubMed Web of Science ®Google Scholar
• Jandeleit-Dahm K, Lassila M, Davis BJ et al. Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice. J. Hypertens.23(11), 2071–2082 (2005).
   PubMed Web of Science ®Google Scholar
• Grady EF, Sechi LA, Griffin CA, Schambelan M, Kalinyak JE. Expression of AT2 receptors in the developing rat fetus. J. Clin. Invest.88(3), 921–933 (1991).
   PubMed Web of Science ®Google Scholar
• Sadoshima J. Cytokine actions of angiotensin II. Circ. Res.86(12), 1187–1189 (2000).
   PubMed Web of Science ®Google Scholar
• Pinaud F, Bocquet A, Dumont O et al. Paradoxical role of angiotensin II type 2 receptors in resistance arteries of old rats. Hypertension50(1), 96–102 (2007).
   PubMed Web of Science ®Google Scholar
• Levy BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin–angiotensin system. Circulation109(1), 8–13 (2004).
   PubMed Web of Science ®Google Scholar
• Senbonmatsu T, Saito T, Landon EJ et al. A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy. EMBO J.22(24), 6471–6482 (2003).
   PubMedGoogle Scholar
• D’Amore A, Black MJ, Thomas WG. The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy. Hypertension46(6), 1347–1354 (2005).
   PubMed Web of Science ®Google Scholar
• Waseda Y, Yasui M, Nishizawa Y et al. Angiotensin II type 2 receptor antagonist reduces bleomycin-induced pulmonary fibrosis in mice. Respir. Res.9, 43 (2008).
   PubMedGoogle Scholar
• Kaschina E, Grzesiak A, Li J et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin–angiotensin system in myocardial infarction? Circulation118(24), 2523–2532 (2008).
   PubMed Web of Science ®Google Scholar
• Soro-Paavonen A, Watson AM, Li J et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes57(9), 2461–2469 (2008).
   PubMed Web of Science ®Google Scholar
• Koitka A, Cao Z, Koh P et al. Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes. Diabetologia53(3), 584–592 (2010).
   PubMedGoogle Scholar
• Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care19(3), 257–267 (1996).
   PubMed Web of Science ®Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature414(6865), 813–820 (2001).
   PubMed Web of Science ®Google Scholar
• Kiritoshi S, Nishikawa T, Sonoda K et al. Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathy. Diabetes52(10), 2570–2577 (2003).
   PubMed Web of Science ®Google Scholar
• Ceriello A, Dello Russo P, Amstad P, Cerutti P. High glucose induces antioxidant enzymes in human endothelial cells in culture; evidence linking hyperglycemia and oxidative stress. Diabetes45(4), 471–477 (1996).
   PubMed Web of Science ®Google Scholar
• Guzik TJ, Harrison DG. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov. Today11(11–12), 524–533 (2006).
   PubMed Web of Science ®Google Scholar
• Tousoulis D, Antoniades C, Koumallos N et al. Novel therapies targeting vascular endothelium. Endothelium13(6), 411–421 (2006).
   PubMed Web of Science ®Google Scholar
• Da Ros R, Assaloni R, Ceriello A. Antioxidant therapy in diabetic complications: what is new? Curr. Vasc. Pharmacol.2(4), 335–341 (2004).
   PubMedGoogle Scholar
• Lee IM, Cook NR, Gaziano JM et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study: a randomized controlled trial. JAMA294(1), 56–65 (2005).
   PubMed Web of Science ®Google Scholar
• Sesso HD, Buring JE, Christen WG et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA300(18), 2123–2133 (2008).
   PubMed Web of Science ®Google Scholar
• Marchioli R, Levantesi G, Macchia A et al. Vitamin E increases the risk of developing heart failure after myocardial infarction: results from the GISSI-Prevenzione trial. J. Cardiovasc. Med.7(5), 347–350 (2006).
   Google Scholar
• Stocker R. The ambivalence of vitamin E in atherogenesis. Trends Biochem. Sci.24(6), 219–223 (1999).
   PubMed Web of Science ®Google Scholar
• Thomas SR, Stocker R. Molecular action of vitamin E in lipoprotein oxidation: implications for atherosclerosis. Free Radic. Biol. Med.28(12), 1795–1805 (2000).
   PubMed Web of Science ®Google Scholar
• Graham D, Huynh NN, Hamilton CA et al. Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension54(2), 322–328 (2009).
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed. Pharmacother.59(7), 365–373 (2005).
   PubMed Web of Science ®Google Scholar
• Lewis P, Stefanovic N, Pete J et al. Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation115(16), 2178–2187 (2007).
   PubMed Web of Science ®Google Scholar
• Torzewski M, Ochsenhirt V, Kleschyov AL et al. Deficiency of glutathione peroxidase-1 accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol.27(4), 850–857 (2007).
   PubMed Web of Science ®Google Scholar
• Blankenberg S, Rupprecht HJ, Bickel C et al. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N. Engl. J. Med.349(17), 1605–1613 (2003).
   PubMed Web of Science ®Google Scholar
• Hamanishi T, Furuta H, Kato H et al. Functional variants in the glutathione peroxidase-1 (GPx-1) gene are associated with increased intima–media thickness of carotid arteries and risk of macrovascular diseases in Japanese Type 2 diabetic patients. Diabetes53(9), 2455–2460 (2004).
   PubMed Web of Science ®Google Scholar
• Winter JP, Gong Y, Grant PJ, Wild CP. Glutathione peroxidase 1 genotype is associated with an increased risk of coronary artery disease. Coron. Artery Dis.14(2), 149–153 (2003).
   PubMedGoogle Scholar
• Koller LD, Exon JH. The two faces of selenium-deficiency and toxicity are similar in animals and man. Can. J. Vet. Res.50(3), 297–306 (1986).
   PubMed Web of Science ®Google Scholar
• Allan CB, Lacourciere GM, Stadtman TC. Responsiveness of selenoproteins to dietary selenium. Annu. Rev. Nutr.19, 1–16 (1999).
   PubMed Web of Science ®Google Scholar
• Bhabak KP, Mugesh G. Synthesis, characterization, and antioxidant activity of some ebselen analogues. Chemistry13(16), 4594–4601 (2007).
   PubMed Web of Science ®Google Scholar
• Sies H. Ebselen. A selenoorganic compound as glutathione peroxidase mimic. Free Radic. Biol. Med.14(3), 313–323 (1993).
   PubMed Web of Science ®Google Scholar
• Sui H, Wang W, Wang PH, Liu LS. Effect of glutathione peroxidase mimic ebselen (PZ51) on endothelium and vascular structure of stroke-prone spontaneously hypertensive rats. Blood Press.14(6), 366–372 (2005).
   PubMed Web of Science ®Google Scholar
• Davis MT, Bartfay WJ. Ebselen decreases oxygen free radical production and iron concentrations in the hearts of chronically iron-overloaded mice. Biol. Res. Nurs.6(1), 37–45 (2004).
   PubMedGoogle Scholar
• Sies H, Masumoto H. Ebselen as a glutathione peroxidase mimic and as a scavenger of peroxynitrite. Adv. Pharmacol.38, 229–246 (1997).
   PubMedGoogle Scholar
• Chew P, Yuen DY, Koh P et al. Site-specific antiatherogenic effect of the antioxidant ebselen in the diabetic apolipoprotein E-deficient mouse. Arterioscler. Thromb. Vasc. Biol.29(6), 823–830 (2009).
   PubMed Web of Science ®Google Scholar
• Chew P, Yuen DY, Stefanovic N et al. Antiatherosclerotic and renoprotective effects of ebselen in the diabetic apolipoprotein E/GPx1-double knockout mouse. Diabetes59(12), 3198–3207 (2010).
   PubMed Web of Science ®Google Scholar
• Brodsky SV, Gealekman O, Chen J et al. Prevention and reversal of premature endothelial cell senescence and vasculopathy in obesity-induced diabetes by ebselen. Circ. Res.94(3), 377–384 (2004).
   PubMedGoogle Scholar
• Khatri JJ, Johnson C, Magid R et al. Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation109(4), 520–525 (2004).
   PubMed Web of Science ®Google Scholar
• Hort MA, Straliotto MR, Netto PM, Da Rocha JB, De Bem AF, Ribeiro-Do-Valle RM. Diphenyl diselenide effectively reduces atherosclerotic lesions in LDLR -/- mice by attenuation of oxidative stress and inflammation. J. Cardiovasc. Pharmacol.58(1), 91–101 (2011).
   PubMed Web of Science ®Google Scholar
• Sarma BK, Mugesh G. Glutathione peroxidase (GPx)-like antioxidant activity of the organoselenium drug ebselen: unexpected complications with thiol exchange reactions. J. Am. Chem. Soc.127(32), 11477–11485 (2005).
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Sano K, Takakura K et al. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke29(1), 12–17 (1998).
   PubMed Web of Science ®Google Scholar
• Schiele F. Renal dysfunction and coronary disease: a high-risk combination. J. Nephrol.22(1), 39–45 (2009).
   PubMed Web of Science ®Google Scholar
• Okamura DM, Himmelfarb J. Tipping the redox balance of oxidative stress in fibrogenic pathways in chronic kidney disease. Pediatr. Nephrol.24(12), 2309–2319 (2009).
   PubMed Web of Science ®Google Scholar
• Chander PN, Gealekman O, Brodsky SV et al. Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen. J. Am. Soc. Nephrol.15(9), 2391–2403 (2004).
   PubMed Web of Science ®Google Scholar
• Yoshizumi M, Kogame T, Suzaki Y et al. Ebselen attenuates oxidative stress-induced apoptosis via the inhibition of the c-Jun N-terminal kinase and activator protein-1 signalling pathway in PC12 cells. Br. J. Pharmacol.136(7), 1023–1032 (2002).
   PubMedGoogle Scholar
• Yoshizumi M, Fujita Y, Izawa Y et al. Ebselen inhibits tumor necrosis factor-alpha-induced c-Jun N-terminal kinase activation and adhesion molecule expression in endothelial cells. Exp. Cell Res.292(1), 1–10 (2004).
   PubMedGoogle Scholar
• Ali N, Yoshizumi M, Tsuchiya K et al. Ebselen inhibits p38 mitogen-activated protein kinase-mediated endothelial cell death by hydrogen peroxide. Eur. J. Pharmacol.485(1–3), 127–135 (2004).
   PubMedGoogle Scholar
• Sarker KP, Biswas KK, Rosales JL et al. Ebselen inhibits NO-induced apoptosis of differentiated PC12 cells via inhibition of ASK1-p38 MAPK-p53 and JNK signaling and activation of p44/42 MAPK and Bcl-2. J. Neurochem.87(6), 1345–1353 (2003).
   PubMed Web of Science ®Google Scholar
• Abe J, Berk BC. Reactive oxygen species as mediators of signal transduction in cardiovascular disease. Trends Cardiovasc. Med.8(2), 59–64 (1998).
   PubMed Web of Science ®Google Scholar
• Bu DX, Rai V, Shen X et al. Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice. Circ. Res.106(6), 1040–1051 (2010).
   PubMed Web of Science ®Google Scholar
• Park L, Raman KG, Lee KJ et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med.4(9), 1025–1031 (1998).
   PubMed Web of Science ®Google Scholar
• Kislinger T, Tanji N, Wendt T et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol.21(6), 905–910 (2001).
   PubMed Web of Science ®Google Scholar
• Schleicher E, Friess U. Oxidative stress, AGE, and atherosclerosis. Kidney Int. Suppl.106, S17–S26 (2007).
   Google Scholar
• Forbes JM, Yee LT, Thallas V et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes53(7), 1813–1823 (2004).
   PubMed Web of Science ®Google Scholar
• Candido R, Forbes JM, Thomas MC et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ. Res.92(7), 785–792 (2003).
   PubMed Web of Science ®Google Scholar
• Ueno H, Koyama H, Shoji T et al. Receptor for advanced glycation end-products (RAGE) regulation of adiposity and adiponectin is associated with atherogenesis in ApoE-deficient mouse. Atherosclerosis211(2), 431–436 (2010).
   PubMed Web of Science ®Google Scholar
• Wendt T, Harja E, Bucciarelli L et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of Type 2 diabetes. Atherosclerosis185(1), 70–77 (2006).
   PubMed Web of Science ®Google Scholar
• Harja E, Bu DX, Hudson BI et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in ApoE-/- mice. J. Clin. Invest.118(1), 183–194 (2008).
   PubMed Web of Science ®Google Scholar
• Sun L, Ishida T, Yasuda T et al. RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice. Cardiovasc. Res.82(2), 371–381 (2009).
   PubMed Web of Science ®Google Scholar
• Sakaguchi T, Yan SF, Yan SD et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J. Clin. Invest.111(7), 959–972 (2003).
   PubMed Web of Science ®Google Scholar
• Zhou Z, Wang K, Penn MS et al. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation107(17), 2238–2243 (2003).
   PubMed Web of Science ®Google Scholar
• Bucciarelli LG, Wendt T, Qu W et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation106(22), 2827–2835 (2002).
   PubMed Web of Science ®Google Scholar
• Al-Mesallamy HO, Hammad LN, El-Mamoun TA, Khalil BM. Role of advanced glycation end product receptors in the pathogenesis of diabetic retinopathy. J. Diabetes Complications25(3), 168–174 (2011).
   PubMedGoogle Scholar
• Katakami N, Matsuhisa M, Kaneto H et al. Decreased endogenous secretory advanced glycation end product receptor in Type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care28(11), 2716–2721 (2005).
   PubMed Web of Science ®Google Scholar
• Srikanth V, Maczurek A, Phan T et al. Advanced glycation end products and their receptor RAGE in Alzheimer’s disease. Neurobiol. Aging.32(5), 763–777 (2011).
   PubMed Web of Science ®Google Scholar
• Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J. Clin. Endocrinol. Metab.93(4), 1143–1152 (2008).
   PubMed Web of Science ®Google Scholar
• Oozawa S, Mori S, Kanke T et al. Effects of HMGB1 on ischemia–reperfusion injury in the rat heart. Circ. J.72(7), 1178–1184 (2008).
   PubMedGoogle Scholar
• Fiuza C, Bustin M, Talwar S et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood101(7), 2652–2660 (2003).
   PubMed Web of Science ®Google Scholar
• Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol. Rev.220, 35–46 (2007).
   PubMed Web of Science ®Google Scholar
• Yang H, Ochani M, Li J et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl Acad. Sci. USA101(1), 296–301 (2004).
   PubMed Web of Science ®Google Scholar
• Mosevitsky MI, Novitskaya VA, Iogannsen MG, Zabezhinsky MA. Tissue specificity of nucleo-cytoplasmic distribution of HMG1 and HMG2 proteins and their probable functions. Eur. J. Biochem.185(2), 303–310 (1989).
   PubMed Web of Science ®Google Scholar
• Kalinina N, Agrotis A, Antropova Y et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler. Thromb. Vasc. Biol.24(12), 2320–2325 (2004).
   PubMed Web of Science ®Google Scholar
• Inoue K, Kawahara K, Biswas KK et al. HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc. Pathol.16(3), 136–143 (2007).
   PubMed Web of Science ®Google Scholar
• Yan XX, Lu L, Peng WH et al. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and Type 2 diabetic patients. Atherosclerosis205(2), 544–548 (2009).
   PubMed Web of Science ®Google Scholar
• Hu X, Jiang H, Bai Q et al. Increased serum HMGB1 is related to the severity of coronary artery stenosis. Clin. Chim. Acta.406(1–2), 139–142 (2009).
   PubMedGoogle Scholar
• Kanellakis P, Agrotis A, Kyaw TS et al. High-mobility group box protein 1 neutralization reduces development of diet-induced atherosclerosis in apolipoprotein e-deficient mice. Arterioscler. Thromb. Vasc. Biol.31(2), 313–319 (2011).
   PubMed Web of Science ®Google Scholar
• Volz HC, Seidel C, Laohachewin D et al. HMGB1: the missing link between diabetes mellitus and heart failure. Basic Res. Cardiol.105(6), 805–820 (2010).
   PubMed Web of Science ®Google Scholar
• Branco-Madeira F, Lambrecht BN. High mobility group box-1 recognition: the beginning of a RAGEless era? EMBO Mol. Med.2(6), 193–195 (2010).
   PubMed Web of Science ®Google Scholar
• Bianchi ME. HMGB1 loves company. J. Leukoc. Biol.86(3), 573–576 (2009).
   PubMed Web of Science ®Google Scholar
• Kim J, Sohn E, Kim CS, Jo K, Kim JS. The role of high-mobility group box-1 protein in the development of diabetic nephropathy. Am. J. Nephrol.33(6), 524–529 (2011).
   PubMed Web of Science ®Google Scholar
• Hagiwara S, Iwasaka H, Hasegawa A, Koga H, Noguchi T. Effects of hyperglycemia and insulin therapy on high mobility group box 1 in endotoxin-induced acute lung injury in a rat model. Crit. Care Med.36(8), 2407–2413 (2008).
   PubMed Web of Science ®Google Scholar
• Dasu MR, Devaraj S, Park S, Jialal I. Increased Toll-like receptor (TLR) activation and TLR ligands in recently diagnosed Type 2 diabetic subjects. Diabetes Care33(4), 861–868 (2010).
   PubMed Web of Science ®Google Scholar
• Pachydaki SI, Tari SR, Lee SE et al. Upregulation of RAGE and its ligands in proliferative retinal disease. Exp. Eye Res.82(5), 807–815 (2006).
   PubMed Web of Science ®Google Scholar
• Onan D, Hannan RD, Thomas WG. Urotensin II: the old kid in town. Trends Endocrinol. Metab.15(4), 175–182 (2004).
   PubMed Web of Science ®Google Scholar
• Onan D, Pipolo L, Yang E, Hannan RD, Thomas WG. Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol. Endocrinol.18(9), 2344–2354 (2004).
   PubMed Web of Science ®Google Scholar
• Pearson D, Shively JE, Clark BR et al. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc. Natl Acad. Sci. USA77(8), 5021–5024 (1980).
   PubMed Web of Science ®Google Scholar
• Coulouarn Y, Jegou S, Tostivint H, Vaudry H, Lihrmann I. Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors. FEBS Lett.457(1), 28–32 (1999).
   PubMed Web of Science ®Google Scholar
• Mori H, Matsunaga K, Tanakamaru Y et al. Effects of protocatechuic acid, S-methylmethanethiosulfonate or 5-hydroxy-4-(2-phenyl-(E)ethenyl)-2(5H)-furanone(KYN-54) on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced pulmonary carcinogenesis in mice. Cancer Lett.135(2), 123–127 (1999).
   PubMedGoogle Scholar
• Itoh H, Mcmaster D, Lederis K. Functional receptors for fish neuropeptide urotensin II in major rat arteries. Eur. J. Pharmacol.149(1–2), 61–66 (1988).
   PubMedGoogle Scholar
• Wang ZJ, Shi LB, Xiong ZW et al. Alteration of vascular urotensin II receptor in mice with apolipoprotein E gene knockout. Peptides27(4), 858–863 (2006).
   PubMedGoogle Scholar
• Bousette N, Patel L, Douglas SA, Ohlstein EH, Giaid A. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis176(1), 117–123 (2004).
   PubMed Web of Science ®Google Scholar
• Maguire JJ, Kuc RE, Wiley KE, Kleinz MJ, Davenport AP. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides25(10), 1767–1774 (2004).
   PubMed Web of Science ®Google Scholar
• Ames RS, Sarau HM, Chambers JK et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature401(6750), 282–286 (1999).
   PubMed Web of Science ®Google Scholar
• Totsune K, Takahashi K, Arihara Z et al. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides25(10), 1809–1814 (2004).
   PubMed Web of Science ®Google Scholar
• Suguro T, Watanabe T, Kodate S et al. Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes. Clin. Sci. (Lond.)115(11), 327–334 (2008).
   PubMed Web of Science ®Google Scholar
• Wassef L, Langham RG, Kelly DJ. Vasoactive renal factors and the progression of diabetic nephropathy. Curr. Pharm. Des.10(27), 3373–3384 (2004).
   PubMedGoogle Scholar
• Papadopoulos P, Bousette N, Al-Ramli W et al. Targeted overexpression of the human urotensin receptor transgene in smooth muscle cells: effect of UT antagonism in ApoE knockout mice fed with Western diet. Atherosclerosis204(2), 395–404 (2009).
   PubMedGoogle Scholar
• Jay MA, Ren J. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and Type 2 diabetes mellitus. Curr. Diabetes Rev.3(1), 33–39 (2007).
   PubMedGoogle Scholar
• Calkin AC, Forbes JM, Smith CM et al. Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler. Thromb. Vasc. Biol.25(9), 1903–1909 (2005).
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis. N. Engl. J. Med.357(1), 28–38 (2007).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Wolski K et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with Type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA299(13), 1561–1573 (2008).
   PubMed Web of Science ®Google Scholar
• Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care27(7), 1647–1653 (2004).
   PubMed Web of Science ®Google Scholar
• Rizos CV, Elisaf MS, Mikhailidis DP, Liberopoulos EN. How safe is the use of thiazolidinediones in clinical practice? Expert Opin. Drug Saf.8(1), 15–32 (2009).
   PubMed Web of Science ®Google Scholar
• Calkin AC, Cooper ME, Jandeleit-Dahm KA, Allen TJ. Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia49(4), 766–774 (2006).
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet366(9500), 1849–1861 (2005).
   PubMed Web of Science ®Google Scholar
• Buse JB, Bigger JT, Byington RP et al.; ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am. J. Cardiol.99(12A), 21i–33i (2007).
   PubMedGoogle Scholar
• Dicembrini I, Pala L, Rotella CM. From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy. Exp. Diabetes Res.898913 (2011).
   PubMedGoogle Scholar